Study to Assess Impact of Dietary Supplement on Sleep Health

NCT ID: NCT05971771

Last Updated: 2023-08-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-08-01

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Sleep is essential for health and wellness. Sleep disruption can occur due to emotional stress, advancing age, hormonal imbalance, medications, and many other causes, some of which are presently unknown. Most pharmaceutical sleep products artificially induce sedation without providing quality sleep. Thus, a need exists for safe dietary supplement to promote and support healthy sleep that will encourage restful sleep. This study will examine the efficacy, tolerance, and safety of sleep supplement as compared to a placebo.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sleep

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

A double-blind, placebo controlled, parallel designed study in healthy subjects
Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors
Products will be delivered in forms that it will not be discernable (to participant, investigator, or care provider) as to which product is active or placebo

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active: Sleep Supplement containing Magnesium and Saffron Extract

Powder that is to be mixed into 3oz. of water, 30-60 minutes before going to bed

Group Type EXPERIMENTAL

Treatment

Intervention Type DIETARY_SUPPLEMENT

14mg saffron extract and 250mg magnesium citrate that is powder that is mixed in 3-4 oz of water and consumed 30-60 minutes before going to bed

Placebo

Placebo that is 2 softgels that will be taken with water, 30-60 minutes prior to going to bed.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Two softgels to be taken with water that is to be consumed approximately 30-60 minutes before going to bed

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo

Two softgels to be taken with water that is to be consumed approximately 30-60 minutes before going to bed

Intervention Type OTHER

Treatment

14mg saffron extract and 250mg magnesium citrate that is powder that is mixed in 3-4 oz of water and consumed 30-60 minutes before going to bed

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Placebo Supplement Supplement for supporting sleep

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The subject is male or female 20-60 years of age at the time of informed consent.
* Recorded baseline BMI is ≥18.5 and ≤29.9 kg/m2.
* A score of 5 or higher on the Pittsburgh Sleep Quality Index.
* Willing and able to give informed consent
* Willing to maintain consistent diet and physical activity through the study period.
* Willing to limit alcohol consumption to ≤14 drinks per week, no more than 4 drinks at a time, and no more than 1 drink within 4h of bedtime.
* Willing to limit caffeine consumption to no more than 4 servings per day and no caffeine within 6h of bedtime.

Exclusion Criteria

* Could not or did not want to participate in clinical study.
* Taken nutritional supplements for sleep or stress in the previous 6 months.
* Have received non-pharmacological treatment for sleep disorders (eg. Cognitive behavioral therapy, relation therapy) in previous 6 months
* Any known allergy or intolerance to any of the ingredients contained in supplement.
* Planned surgical procedure during the course of the study.
* Used nicotine in the past 6 months.
* Have a major psychiatric disorder as determined by the Mini International Neuropsychiatric Inventory
* A history of unconventional sleep pattern, a diagnosed sleep disorder, or chronic medical condition that could affect energy/fatigue levels.
* Consume more than 400mg of caffeine per day in the past 2 weeks.
* Used any psychotropic medications, stimulants, cannabis, non-registered drug products, or illicit substances in the past 4 weeks.
* At risk of drug or alcohol abuse
* Used any sleep aids in the past 2 weeks.
* Employed in night shift work or rotational shift work
* Currently pregnant, nursing, planning to become pregnant, or unwilling to use a medically approved form of contraception will be excluded.
* Individuals who sleep more than 10 hours.
* Typically take a nap during the day.
* Those planning travel or vacation during the study period.
Minimum Eligible Age

20 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Dermatology Consulting Services, High Point NC

OTHER

Sponsor Role collaborator

Pharmanex

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Zoe D Diana, MD

Role: CONTACT

336-841-2040

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DCS-7-23

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Ashwagandha for Nighttime Waking
NCT07151261 RECRUITING NA